Prep for USMLEPrep for USMLE
         Forum      |     Resources New Posts   |   Register   |   Login


Post Reply  
  • 0/5
  • 1
  • 2
  • 3
  • 4
  • 5

Author9 Posts

A well-done randomized trial evaluated the efficacy of full-dose
subcutaneous low-molecular-weight heparin (LMWH) versus
warfarin (international normalized ratio [INR], 2.0-3.0) in
reducing recurrent venous thromboembolism (VTE) in a group
of patients with VTE and active cancer. The study duration was
6 months. During that time, 17% of the cancer patients receiving
warfarin had recurrent VTE compared with 9% of patients
receiving full-dose subcutaneous LMWH. On the basis of this
information, how many patients need to be treated for 6 months
with subcutaneous LMWH to prevent one additional VTE?

a. 17%
b. 12%
c. 9%
d. 8%
e. 4%




grin u have a passion for math, rkmehta

answer is B

You are asked to determine the number needed to treat (NNT) in
a randomized trial reporting that the LMWH-treated group had an
event rate of 9%. Therefore, the experimental event rate (EER) is 9%.

The warfarin-treated group had an EER of 17%. Therefore,
the control event rate (CER) is 17%.

NNT = 1/ARR, where ARR = (CER − EER). In this case, 17% − 9% = 8%.

Therefore, NNT = 1/.08 or about 12.


OOOPS....ITS 'one additional vte' i should improve my reading..sad

no passion for maths....old days r gone...iit ws in school days....sad


i hv a passion for USMLE...grin

when z ur xam avir??


it was, in March

now i read CS cases in the evening and try to maintain internal med fresh in the morninggrin


so u r helping us...smiling face keep it up...wats ur score in ck? i m sure >250...smiling face


sticking out tongue 93


bt its knowledge wat matters....wink

Bookmark and Share

Login or Register to post messages

show Similar forum topics

show Related resources

Advertise | Support | Privacy | TOS | Premium | Contact